REVESTIVE 1.25 mg, powder and solvent for solution for injection 28 bottles of 0.5 ml
Active ingredients: Teduglutide
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for solution for injection28 bottles of 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- REVESTIVE 1,25 mg, poudre et solvant pour solution injectable
- Pharmaceutical form
- poudre et solvant pour solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 28 flacon(s) en verre de 1,25 mg - 28 seringue(s) préremplie(s) en verre de 0,5 ml avec piston(s)
- Marketing authorisation holder
- TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 10 Apr 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
63112361CIP73011505CIP133400930115053Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉDUGLUTIDEpoudre | 1,25 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.